Real‐world performance of the MiniMed™ 670G system in Europe
Open Access
- 7 May 2021
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 23 (8) , 1942-1949
Abstract
Aim: To evaluate the real‐world performance of the MiniMed 670G system in Europe, in individuals with diabetes. Materials and Methods: Data uploaded from October 2018 to July 2020 by individuals living in Europe were aggregated and retrospectively analysed. The mean glucose management indicator (GMI), percentage of time spent within (TIR), below (TBR) and above (TAR) glycaemic ranges, system use and insulin consumed in users with 10 or more days of sensor glucose data after initial Auto Mode start were determined. Another analysis based on suboptimally (GMI > 8.0%) and well‐controlled (GMI < 7.0%) glycaemia pre‐Auto Mode initiation was also performed. Results: Users ( N = 14 899) spent a mean of 81.4% of the time in Auto Mode and achieved a mean GMI of 7.0% ± 0.4%, TIR of 72.0% ± 9.7%, TBR less than 3.9 mmol/L of 2.4% ± 2.1% and TAR more than 10 mmol/L of 25.7% ± 10%, after initiating Auto Mode. When compared with pre‐Auto Mode initiation, GMI was reduced by 0.3% ± 0.4% and TIR increased by 9.6% ± 9.9% ( P < .0001 for both). Significantly improved glycaemic control was observed irrespective of pre‐Auto Mode GMI levels of less than 7.0% or of more than 8.0%. While the total daily dose of insulin increased for both groups, a greater increase was observed in the latter, an increase primarily due to increased basal insulin delivery. By contrast, basal insulin decreased slightly in well‐controlled users. Conclusions: Most MiniMed 670G system users in Europe achieved TIR more than 70% and GMI less than 7% while minimizing hypoglycaemia, in a real‐world environment. These international consensus‐met outcomes were enabled by automated insulin delivery meeting real‐time insulin requirements adapted to each individual user.Keywords
This publication has 17 references indexed in Scilit:
- State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016–2018Diabetes Technology & Therapeutics, 2019
- Safety Evaluation of the MiniMed 670G System in Children 7–13 Years of Age with Type 1 DiabetesDiabetes Technology & Therapeutics, 2019
- Glucose Management Indicator (GMI): A New Term for Estimating A1C From Continuous Glucose MonitoringDiabetes Care, 2018
- Revisiting the Relationships Between Measures of Glycemic Control and Hypoglycemia in Continuous Glucose Monitoring Data SetsDiabetes Care, 2017
- Glucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 DiabetesDiabetes Technology & Therapeutics, 2017
- Hybrid Closed-Loop Insulin Delivery in Type 1 Diabetes During Supervised Outpatient ConditionsJournal of Diabetes Science and Technology, 2016
- Risk Factors Associated With Severe Hypoglycemia in Older Adults With Type 1 DiabetesDiabetes Care, 2015
- Hypoglycemia Reduction and Changes in Hemoglobin A1c in the ASPIRE In-Home StudyDiabetes Technology & Therapeutics, 2015
- Threshold-Based Insulin-Pump Interruption for Reduction of HypoglycemiaNew England Journal of Medicine, 2013
- The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes MellitusNew England Journal of Medicine, 1993